Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology

  • Published : 2014.02.28


Background: The overall prognosis for cancers of unknown primary (CUP) is poor, median overall survival (OS) being 6-12 months. We evaluated our multicentric retrospective experience for CUP administered docetaxel and cisplatin combination therapy. Materials and Methods: A total of 29 patients that were pathologically confirmed subtypes of CUP were included in the study. The combination of docetaxel ($75mg/m^2$, day 1) and cisplatin ($75mg/m^2$, day 1) was performed as a first line regimen every 21 days. Results: The median age was 51 (range: 27-68). Some 17 patients had multimetastatic disease on the inital diagnosis. Histopathological diagnoses were well-moderate differentiated adenocarcinoma (51.7%), undifferentiated carcinoma (27.6%), squamous cell cancer (13.8%), mucoepidermoid carcinoma (3.4%) and neuroendocrine differentiated carcinoma (3.4%). Median number of cycles was 3 (range: 1-6). Objective response rate was 37.9% and clinical benefit was 58.6%. Median progression free survival (PFS) and overall survival (OS) were 6 months (range: 4.3-7.7 months) and 16 months (range: 8.1-30.9 months), respectively. Fourteen patients (60.8%) were treated in a second line setting. There was no treatment related death. Most common toxicities were nausia-vomiting (44.6%) and fatigue (34.7%), serious cases (grade 3/4) suffering nausia-vomiting (10.3%), neutropenia (13.8%) and febrile neutropenia (n=1). Conclusion: The combination of cisplatin and docetaxel is an effective regimen for selected patients with CUP.


  1. Mukai H, Katsumata N, Ando M, Watanabe T (2010). Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol, 33, 32-5.
  2. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009.
  3. Nishimori H, Takahashi S, Kiura K, et al (2010). Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan. Acta Med Okayama. 64, 285-91.
  4. Pavlidis N, Pentheroudakis G (2012). Cancer of unknown primary site. Lancet, 379, 1428-35.
  5. Hemminki K, Bevier M, Hemminki A, Sundquist J (2012). Survival in cancer of unknown primary site: populationbased analysis by site and histology. Ann Oncol, 23, 1854-63
  6. Pouessel D, Culine S, Becht C, et al (2004). Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer, 100, 1257-61.
  7. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al (2006). Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 107, 2698-705.
  8. Yakushiji S, Ando M, Yonemori K, et al (2006). Cancer of unknown primary site: Review of consecutive cases at the national cancer center hospital of japan. Int J Clin Oncol 11, 421-5.
  9. Greco FA, Erland JB, Morrissey LH, et al (2000). Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol, 11, 211-5.
  10. Goldberg RM, Smith FP, Ueno W, Ahlgren JD, Schein PS (1986). 5-Fluorouracil, adriamycin, mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol, 4, 395-9.
  11. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N (2009). Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple treatments meta-analysis. Cancer Treat Rev, 35, 570-3.
  12. Greco FA, Burris 3rd, Erland JB, et al (2000). Carcinoma of unknown primary site. Cancer, 89, 2655-60.<2655::AID-CNCR19>3.0.CO;2-9
  13. Greco FA, Gray J, Burris HA 3rd, Erland JB, Morrissey LH, Hainsworth JD (2001). Taxane based chemotherapy for patients with carcinoma of unknown primary site. Cancer J, 7, 203-12.
  14. Greco FA, Oien K, Erlander M, et al (2012). Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol, 23, 98-304
  15. Hainsworth JD, Spigel DR, Clark BL, et al (2010). Paclitaxel/ carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J, 16, 70-5.
  16. Lazaridis G, Pentheroudakis G, Fountzilas G, Pavlidis N (2008). Liver metastases from cancer of unknown primary (CUPL): a retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature. Cancer Treat Rev, 34, 693-700.
  17. Massard C, Loriot Y, Fizazi K (2011). Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol. 8, 701-10.
  18. Adenis A, Ferte C, Penel N (2010). Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis. Invest New Drugs. 28, 178-84.
  19. Briasoulis E, Kalofonos H, Bafaloukos D, et al (2000). Carboplatin plus paclitaxel in unknown primary carcinoma: A Phase II Hellenic Cooperative Oncology Group study. J Clin Oncol 18, 3101-7.
  20. Culine S, Kramar A, Saghatchian M, et al (2002). Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 20, 4679-83.
  21. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47.
  22. Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J (2010). Prognostic factors in cancer of unknown primary site.Tumori. 96, 111-6.
  23. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G (2011); ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 22, 64-8.

Cited by

  1. Neuroendocrine tumors in the Iran Cancer Institute: Predictive Factors of Patient Survival vol.15, pp.18, 2014,
  2. Anti-cancer Properties of a Sesquiterpene Lactone-bearing Fraction from Artemisia khorassanica vol.16, pp.3, 2015,
  3. A Simple Risk Model to Predict Survival in Patients With Carcinoma of Unknown Primary Origin vol.94, pp.47, 2015,